CN100418554C - 一种治疗强直性脊柱炎的药物及其制备方法 - Google Patents
一种治疗强直性脊柱炎的药物及其制备方法 Download PDFInfo
- Publication number
- CN100418554C CN100418554C CNB2006100207500A CN200610020750A CN100418554C CN 100418554 C CN100418554 C CN 100418554C CN B2006100207500 A CNB2006100207500 A CN B2006100207500A CN 200610020750 A CN200610020750 A CN 200610020750A CN 100418554 C CN100418554 C CN 100418554C
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- medicine
- ankylosing spondylitis
- colla cornus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 61
- 206010002556 Ankylosing Spondylitis Diseases 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 241000522620 Scorpio Species 0.000 claims abstract description 14
- 239000009490 scorpio Substances 0.000 claims abstract description 13
- 235000006463 Brassica alba Nutrition 0.000 claims abstract description 3
- 241000209020 Cornus Species 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 17
- 241001550206 Colla Species 0.000 claims description 16
- 241000131808 Scolopendra Species 0.000 claims description 13
- 239000009636 Huang Qi Substances 0.000 claims description 9
- 239000012141 concentrate Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 3
- 241000545442 Radix Species 0.000 claims description 2
- 241000220262 Sinapis alba Species 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 abstract description 14
- 208000002193 Pain Diseases 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 13
- 230000036407 pain Effects 0.000 abstract description 13
- 210000004369 blood Anatomy 0.000 abstract description 12
- 239000008280 blood Substances 0.000 abstract description 12
- 239000000203 mixture Substances 0.000 abstract description 10
- 230000017531 blood circulation Effects 0.000 abstract description 7
- 239000002775 capsule Substances 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 238000009472 formulation Methods 0.000 abstract description 4
- 238000005728 strengthening Methods 0.000 abstract description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 3
- 208000026435 phlegm Diseases 0.000 abstract description 3
- 239000006187 pill Substances 0.000 abstract description 3
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 244000140786 Brassica hirta Species 0.000 abstract 1
- 235000011371 Brassica hirta Nutrition 0.000 abstract 1
- 241000258920 Chilopoda Species 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 235000021511 Cinnamomum cassia Nutrition 0.000 abstract 1
- 241000123589 Dipsacus Species 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 241000157491 Morinda Species 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 210000003056 antler Anatomy 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 239000003292 glue Substances 0.000 abstract 1
- 235000017524 noni Nutrition 0.000 abstract 1
- 210000001624 hip Anatomy 0.000 description 11
- 210000000988 bone and bone Anatomy 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 231100000614 poison Toxicity 0.000 description 10
- 201000010099 disease Diseases 0.000 description 8
- 208000006820 Arthralgia Diseases 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 210000003127 knee Anatomy 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000007096 poisonous effect Effects 0.000 description 5
- 239000007789 gas Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 231100000915 pathological change Toxicity 0.000 description 4
- 230000036285 pathological change Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- 206010021118 Hypotonia Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 208000017561 flaccidity Diseases 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 231100000862 numbness Toxicity 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000008822 Ankylosis Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 206010023198 Joint ankylosis Diseases 0.000 description 2
- 206010039361 Sacroiliitis Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- -1 amine salt Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 210000004394 hip joint Anatomy 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 210000003131 sacroiliac joint Anatomy 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010002027 Amyotrophy Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- DHHFDKNIEVKVKS-FMOSSLLZSA-N Betanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC(C[C@H]2C([O-])=O)=C1[N+]2=C\C=C\1C=C(C(O)=O)N[C@H](C(O)=O)C/1 DHHFDKNIEVKVKS-FMOSSLLZSA-N 0.000 description 1
- DHHFDKNIEVKVKS-MVUYWVKGSA-N Betanin Natural products O=C(O)[C@@H]1NC(C(=O)O)=C/C(=C\C=[N+]/2\[C@@H](C(=O)[O-])Cc3c\2cc(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)/C1 DHHFDKNIEVKVKS-MVUYWVKGSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010005963 Bone formation increased Diseases 0.000 description 1
- 206010061728 Bone lesion Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010023798 Charybdotoxin Proteins 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010034568 Peripheral coldness Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010058907 Spinal deformity Diseases 0.000 description 1
- 206010072005 Spinal pain Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 235000012677 beetroot red Nutrition 0.000 description 1
- 239000001654 beetroot red Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000002185 betanin Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- CNVQLPPZGABUCM-LIGYZCPXSA-N ctx toxin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H]3CSSC[C@@H](C(N[C@@H](CC=4C5=CC=CC=C5NC=4)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC3=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CO)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3NC=NC=3)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N2)C(C)C)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC1=O)=O)CCSC)C(C)C)[C@@H](C)O)NC(=O)[C@H]1NC(=O)CC1)C1=CC=CC=C1 CNVQLPPZGABUCM-LIGYZCPXSA-N 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 210000002356 skeleton Anatomy 0.000 description 1
- SDKPSXWGRWWLKR-UHFFFAOYSA-M sodium;9,10-dioxoanthracene-1-sulfonate Chemical compound [Na+].O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2S(=O)(=O)[O-] SDKPSXWGRWWLKR-UHFFFAOYSA-M 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗强直性脊柱炎的药物,其主要是由鹿角胶、肉桂、麻黄、白芥子、全蝎、蜈蚣、丹参、枳壳、巴戟天、续断、狗脊、黄芪、当归等,按一定重量配比制备而成。它可以被制备成汤剂、丸、胶囊等剂型。本发明药物具有补肾强督、搜风通络、逐瘀化痰、活血止痛的功能,治疗强直性脊柱炎见效快,治愈率高。
Description
技术领域
本发明涉及一种治疗强直性脊柱炎的药物及制备方法,属中药技术领域。
背景技术
强直性脊柱炎属于风湿病范畴,是血清阴性脊柱关节病中的一种,它是指一种原因尚不很明确,以侵犯脊柱,骶髂关节和髋关节为主的慢性进行性病变以脊柱为主要病变的慢性疾病,病变主要累及骶髂关节,引起脊柱强直和纤维化,造成弯腰、行走活动受限,并可有不同程度的眼、肺、心血管、肾等多个器官的损害。强直性脊柱炎以青年男性多发,20岁左右是发病的高峰年龄。其起病隐匿,病程漫长,反复发作,危害性大,可致脊柱畸形、关节强直因它不同程度地有韧带、肌肉、骨骼的病变,也有自身免疫功能的紊乱,所以又属自身免疫性疾病。疾病的表现形式多种多样,极易误诊,若延误治疗或治疗不当,可造成终身残疾。
中医对强直性脊柱炎的认识历史久远,对本病的描述最早见于公元前475~221年战国时期,根据强直性脊柱炎的临床特征、病机特点及病情演变过程,将其归属于痹症之“骨痹”、“肾痹”、“妊痹”范畴,它又有“复感于邪,内舍于肾”的特点,如《黄帝内经》说:“骨痹不已,复感于邪,内舍于肾”,又说:“肾痹者,尻以代踵,脊以代头”,意思是用臀部代替双足,不能行走,因脊柱弯曲或驼背后远看似头,比较形象地描述了强直性脊柱炎的脊柱、髋关节的畸形改变,说明脊柱强直不能屈伸而致坐起困难。近年来著名医学家焦树德又提出将强直性脊柱炎称之为“大偻”,偻指脊柱弯曲,大偻指病情沉重、脊柱弯曲、背俯的疾病。如《黄帝内经》中说“阴气者,开阖不得,寒气从之,就生大偻”,王冰著说“身体俯曲,不能直立,偻,脊柱弯曲”。
中医认为,“风寒湿三气杂至,合而为痹”,为痹证总的外因。其内因与禀赋不足,肾、督阳虚有关;外因感受寒湿或湿热之邪为主,或与外伤后淤血内阻督脉有关。由于素体虚弱,风寒湿热之外邪乘虚而入,内外合邪,阳气不化,寒邪内蕴,着于筋骨,影响筋骨的营养淖泽,闭阻经络,气血不畅,发为本病。
对于强直性脊柱炎的治疗,目前还没有特别有效的方法。在治疗中应用的治疗非甾体类药物、抗痛风类药物、甾体类抗炎免疫类药物和非类固醇抗炎剂只能改善其症状,不能控制病情的进展;而较多采用的雷公藤制剂虽有一定疗效,但副作用大,对肝及生殖腺有影响,毒害大,不能长期用药(参见中华骨科杂志1984,4(3),133页,郭巨灵著文;雷公藤酊治疗风湿性关节炎和强直性脊柱炎);国内外还采用一些其他药剂如D-青霉素胺、金盐等治疗强直性脊柱炎,但治疗效果很差。
中药包括外用药和内服药两种,外用药治标不治本,效果不好;内服药研究得较多,如中国专利以申请号99117885公开的“一种治疗强直性脊柱炎的药剂及其制备方法”,以申请号01139923.6公开的一种“治疗强直性脊柱炎合并骨头坏死的中药组合物”,以申请号200310115978.4公开的“一种治疗风湿性关节炎、强直性脊柱炎的药物及其制备方法”,这些专利文献所公开的治疗强直性脊柱炎的中药治疗效果并不理想,不能标本兼治。
发明内容
本发明的目的是为了克服上述现有技术的缺点而提供一种能够通过抗炎和调节人体免疫功能控制强直性脊柱炎病情,恢复患者整体功能的中药组合物。
本发明的目的是这样实现的:
本发明药物选择鹿角胶、肉桂、白芥子、麻黄、熟地、丹参、枳壳、巴戟天、狗脊、淫羊藿、全蝎、蜈蚣、续断、黄芪和当归进行组合的,将这些药物组合使得各药物功效产生协同作用,从而能够有效治疗强直性脊柱炎,它主要是由下列重量份的原料药制成:
鹿角胶2-2.5份 肉桂1-2份 白芥子1-2份
麻黄1-1.5份 熟地56份 枳壳2-4份
丹参3-4.5份 巴戟天3-5份 狗脊3-5份
淫羊藿3-4.5份 全蝎1-1.5份 蜈蚣1份
续断34.5份 黄芪3-5份 当归3-5份
其中,选择鹿角胶、肉桂、巴戟天、狗脊、续断、淫羊藿主要是为了温肾、壮脊、强督,因为鹿角胶味甘、气温、入肝肾二经,有补血、益精的功能,主治肾气不足,虚劳羸瘦、腰痛;肉桂味辛、温,功能:补元阳、通血脉,主治命门火衰,肢冷脉微,腰膝冷痛;巴戟天味辛、微温,有补肾阳、强筋骨、祛风湿功能,主治风寒湿痹,腰膝酸痛;狗脊可补肝肾,除风湿,健腰脚,利关节,主治腰背酸痛,膝痛脚弱,寒湿周痹;续断有补肝肾、续筋骨、调血脉的功能,主治腰背酸痛、足膝无力;淫羊藿有补肾壮阳,祛风除湿的功能,主治筋骨挛急,半身不遂,腰膝无力,风湿痹痛,四肢不仁;选择丹参,是因为其味苦、微温,有活血祛瘀,安神宁心,排脓止痛的功能;选用全蝎、蜈蚣主要是因为它们具有搜风、散结、通络、消癥的作用:全蝎味成、辛、平、有毒,具祛风、止痉、通络、解毒之功能;蜈蚣味辛、温有小毒,有祛风、定惊、攻毒、散结之功能,主治中风、惊痛、癥积瘤块;
选用麻黄、白芥子,主要是为了利湿、行气、化痰。麻黄辛苦、温,有发汗、平喘、利水之功能,主治骨节疼痛,风邪顽痹,皮肤不仁;白芥子辛温、无毒,有利气割痰,通络止痛之功能,主治痰饮胸胁胀满疼痛,中风不语,肢体痹痛麻木,跌打肿痛。选用黄芪、当归、熟地主要是为了补气、活血、固卫。黄芪性甘、微温,能益卫固表、养血、生肌、托毒、补中益气,主治一切气衰血虚之证;当归甘辛、温,能补血和血、调经止痛,主治癥瘕结聚、痿痹,血虚、跌扑损伤;熟地味甘、微温,能滋阴、补血,治阴虚血少,腰膝痿弱。上述诸药合方共奏,具有下述四大特点:
一、强脊壮督,扶正祛邪
从根本上治疗强直性脊柱炎,运用平衡阴阳补益肝肾等法扶正,提高人身机体免疫能力;运用搜风、祛湿、活血、逐痰等祛邪,阻断强直性脊柱炎致病因素的再生,达到标本兼治。
二、直达筋骨,修复骨纤维
该中药组合物的活性物质,被人体通过体液直接通达每个病变部位,清除病理改变。对脊柱骨性强直、骨质增生等骨性病变的改善有独特疗效,起效迅速。
三、根除顽痛,不易复发
血活、气行方能止痛,该药物对强直性脊柱炎引起的各部位脊柱关节、肌肉疼痛等疗效显著。经临床验症,病理一经清除,不易复发。
四、安全无毒,不损脏器
纯中药制剂,不含任何激素,,采用的全蝎、蜈蚣的量也在安全范围内,这是本领域的普通技术人员所公知的,安全可靠,无任何毒副作用。
需要进一步说明的是,在《全国中草药汇编》370页和《中药大辞典》934页中详细记载了全蝎的性质和用量,其化学成分:含蝎毒素,为一种含碳、氢、氧、氮.、等元素的毒性蛋白,与蛇及毒虫的神经毒类似,此外,并含三甲胺、甜菜碱、牛黄酸、软脂酸、硬脂酸、胆甾酸、卵磷脂及胺盐等,其毒性加热至100℃.经30分钟即被破坏。
性味:辛、甘、平、有毒
功能:镇痛、熄火、攻毒.
用法用量:用于内服汤剂或丸、散的用量为2.4克-4.5克,研末吞服,每次0.6克-1克。在这种用量范围内对人体来说是非常安全的。
在《全国中草药汇编》882页和《中药大辞典》2474页记载了蜈蚣的性质和用量,其化学成分:含有与蜂毒相似的两种有毒物质即组织胺样物质及溶血蛋白质,此外,尚含酪氨酸,亮氨酸,蚁酸,脂肪油,胆甾醇等。
性味:辛、温、有毒.
功能:镇痉、熄风、解毒.
用法用量:用于内服汤剂或丸,散的用量1-3条(1.5克-4.5克);研末吞服,每次0.6克-1克。在这种用量范围内对人体来说是非常安全的。
本发明药物组分的用量也是经过发明人进行大量摸索总结得出的,各组份用量为在下述重量份范围具有更好的疗效:
鹿角胶2份 肉桂1.5份 白芥子1.5份
麻黄1份 熟地5份 枳壳3份
丹参4份 巴戟天4份 狗脊4份
淫羊藿3.5份 全蝎1份 蜈蚣1份
续断4份 黄芪4份 当归4份
本发明中所述的各种药物均是高效传统中药组合而成,例如可以将这些原料药水煎服,或研成粉末混合均匀制成散剂冲服,或可以加入制备不同剂型时所需的各种常规辅料,如崩解剂、润滑剂、粘合剂等以常规的中药制剂方法制备成任何一种常用口服剂型,如丸剂、散剂、片剂、胶囊剂、口服液等。但为了使该药物的各原料更好地发挥药效,最好选用如下方法制备药物:
a)按上述配方称取各原料药备用;
b)将所述重量配比的药物(鹿角胶除外),加水煎煮两次,每次加水量以没过药面二指为宜,以煎沸后15分钟,合并两次煎液、浓缩形成浓缩物,鹿角胶烊化后与上述浓缩物混合而成。
本药分二次服用,每日一剂。
本发明药物具有补肾强腰、通督化瘀、活筋通络之作用,用于治疗强直性脊柱炎。
具体实施方式
下面结合实施例对本发明作进一步详细说明,但本发明并不只限于这些例子:
以下通过临床疗效观察,来进一步阐述本发明所述药物的有益效果。
1、一般资料:收治患者共30例,其中男20例,女10例。男女之比为2∶1。年龄12岁-16岁10例;17岁-26岁12例;27岁以上8例。其中学生14例,干部1例,农民10例,工人3例,商人1例,教师1例。
2、诊断标准:
(1)中医诊断标准:
初时腰膝酸软、疲倦;腰背强硬,畏寒肢冷、纳差、耳鸣、头昏、肌肉萎缩、知质淡红或淡白、黯紫瘀斑、苔薄白或黄腻;
(2)西医诊断标准:
晨僵、腰骶脊柱疼痛;正常呼吸时胸痛或颈活动时疼痛、僵硬;X线、CT表现为骶髂关节炎、髋关节炎及脊柱竹节样改变。
3、治疗方法:每日中药汤剂口服一剂(分两次早晚服);片、胶囊每日3次,一个月为一个疗程,连用3个疗程。
4、疗效评定标准:显效:晨僵、夜间痛消失,功能改善,基本不必服用解热镇痛药;CT或X线表现有改善或无明显加重。
有效:夜间不痛,晨僵减轻,功能改善,CT或X线表现无明显变化。
无效:症状加重,CT或X线表现骶髂关节炎程度加重。
5、治疗结果:(见表1、2)
表1经治疗后疗效观察
表2经治疗后一月体征改善情况
| 症状 | 晨僵 | 疼痛 | 腰膝酸软 | 疲倦 | 功能恢复 |
| 治疗前(例) | 24 | 30 | 28 | 18 | 0 |
| 治疗后(例) | 4 | 10 | 8 | 2 | 22 |
| 总有效率(%) | 83.3 | 66.6 | 71.4 | 88.8 | 73.2 |
总之,在3个月中,用强脊宁中药组合物治疗30例,结果显效23例,好转6例;无效1例;显效率为76.6%;好转率为20%,总有效率为96%。
以下通过实施例进一步阐明本发明药物的制备方法:
实施例1:本发明药物的口服剂制备:
a)按下述重量配方称取各原料药:
鹿角胶2g,肉桂1.5g,白芥子1.5g,麻黄1g,熟地5g,枳壳3g,丹参4g,巴戟天4g,狗脊4g,淫羊藿3.5g,全蝎1g,蜈蚣1g,续断4g,黄芪4g,当归4g,备用;
b)将所述重量配比的药物(鹿角胶除外),加水煎煮两次,每次加水量以没过药面二指为宜,以煎沸后15分钟,合并两次煎液、浓缩形成浓缩物,鹿角胶烊化后与上述浓缩物混合而成。
实施例2:本发明药物的丸剂制备:
a)按下述重量配方称取各原料药:
鹿角胶2g,肉桂1g,白芥子1g,麻黄1g,熟地5g,枳壳2g,丹参3g,巴戟天3g,狗脊3g,淫羊藿3g,全蝎1g,蜈蚣1g,续断3g,黄芪3g,当归3g,备用;
b)将上述原料药中的麻黄、当归、巴戟天、熟地、狗脊加水煎取浓液,加入蜂蜜、鹿角胶浓缩成药膏;
c)将上述原料药中的白芥子、枳壳、肉桂、黄芪、淫羊藿、全蝎、蜈蚣、续断等药烘干,研细末;
d)将上述细末与上述药膏揉和均匀,切成条状,再揉成小颗粒,即为丸。
实施例3:本发明药物的胶囊剂制备:
a)按下述重量配方称取各原料药:
鹿角胶2.5g,肉桂2g,白芥子2g,麻黄1.5g,熟地6g,枳壳4g,丹参4.5g,巴戟天5g,狗脊5g,淫羊藿4.5g,全蝎1.5g,蜈蚣1g,续断4.5g,黄芪5g,当归5g,备用;
b)将上述原料药物烘干后研细后,装入0号胶囊内而成。
Claims (3)
1. 一种治疗强直性脊柱炎的药物,其特征在于它是由下列重量份的原料药制成:鹿角胶2-2.5份、肉桂1-2份、白芥子1-2份、麻黄1-1.5份、熟地5-6份、枳壳2-4份、丹参3-4.5份、巴戟天3-5份、狗脊3-5份、淫羊藿3-4.5份、全蝎1-1.5份、蜈蚣1份、续断3-4.5份、黄芪3-5份、当归3-5份。
2. 根据权利要求1所述的药物,其特征在于各组份的用量为:鹿角胶2份、肉桂1.5份、白芥子1.5份、麻黄1份、熟地5份、枳壳3份、丹参4份、巴戟天4份、狗脊4份、淫羊藿3.5份、全蝎1份、蜈蚣1份、续断4份、黄芪4份、当归4份。
3. 权利要求1或2所述药物的制备方法,其特征在于按如下步骤进行:
a)按上述配方称取各原料药备用;
b)将除鹿角胶外所述重量配比的药物,加水煎煮两次,每次加水量以没过药面二指为宜,以煎沸后15分钟,合并两次煎液、浓缩形成浓缩物,鹿角胶烊化后与上述浓缩物混合而成。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100207500A CN100418554C (zh) | 2006-04-21 | 2006-04-21 | 一种治疗强直性脊柱炎的药物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100207500A CN100418554C (zh) | 2006-04-21 | 2006-04-21 | 一种治疗强直性脊柱炎的药物及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1876058A CN1876058A (zh) | 2006-12-13 |
| CN100418554C true CN100418554C (zh) | 2008-09-17 |
Family
ID=37508727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100207500A Expired - Fee Related CN100418554C (zh) | 2006-04-21 | 2006-04-21 | 一种治疗强直性脊柱炎的药物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100418554C (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104225532B (zh) * | 2014-09-12 | 2018-03-16 | 郑州中医骨伤病医院 | 治疗强直性脊柱炎的健脾温肾丸 |
| CN105920264A (zh) * | 2016-04-27 | 2016-09-07 | 石良 | 一种强直康复丸、制备方法及其服用方法 |
| CN106038804B (zh) * | 2016-06-29 | 2020-07-24 | 南京中医药大学 | 一种治疗强直性脊柱炎的中药制剂 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1244414A (zh) * | 1999-07-27 | 2000-02-16 | 郭祥穆 | 免疫风湿胶囊 |
| CN1422639A (zh) * | 2001-11-28 | 2003-06-11 | 丁原镛 | 一种治疗风湿、类风湿性疾病的口服药物 |
| CN1535704A (zh) * | 2003-04-09 | 2004-10-13 | 吴荣华 | 主治强直性脊柱炎的鲜中药外敷药剂 |
| CN1682811A (zh) * | 2005-02-22 | 2005-10-19 | 黄资源 | 一种治疗强直性脊柱炎的强脊壮骨丸 |
-
2006
- 2006-04-21 CN CNB2006100207500A patent/CN100418554C/zh not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1244414A (zh) * | 1999-07-27 | 2000-02-16 | 郭祥穆 | 免疫风湿胶囊 |
| CN1422639A (zh) * | 2001-11-28 | 2003-06-11 | 丁原镛 | 一种治疗风湿、类风湿性疾病的口服药物 |
| CN1535704A (zh) * | 2003-04-09 | 2004-10-13 | 吴荣华 | 主治强直性脊柱炎的鲜中药外敷药剂 |
| CN1682811A (zh) * | 2005-02-22 | 2005-10-19 | 黄资源 | 一种治疗强直性脊柱炎的强脊壮骨丸 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1876058A (zh) | 2006-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101411802B (zh) | 一种治疗骨质增生的黑膏药及其制备方法 | |
| CN101537168B (zh) | 一种治疗颈椎病及骨关节疾病的中药组合物及其制备方法 | |
| CN101129978A (zh) | 一种内服治疗抑郁症的中药组合物 | |
| CN106540230A (zh) | 一种用于缓解颈椎病、腰椎病等疾病的精油及其制备方法 | |
| CN101204562B (zh) | 治疗慢性损伤、关节炎、关节积液、颈肩腰腿痛的外用药 | |
| CN102247497A (zh) | 一种治疗类风湿性关节炎的中成药 | |
| CN103977130A (zh) | 治疗风湿腰椎间盘突出颈椎病骨质增生四肢麻木的中药 | |
| CN101690768B (zh) | 筋痹活络丸 | |
| CN101002873B (zh) | 一种治疗复发性痛风的药物及其制备方法 | |
| CN100418554C (zh) | 一种治疗强直性脊柱炎的药物及其制备方法 | |
| CN106039245A (zh) | 一种治疗风湿骨病的外用中药矿泉泥及其制备方法 | |
| CN102600256B (zh) | 一种用于跌打损伤中药组合物 | |
| CN101700389B (zh) | 一种治疗风湿、类风湿疾病的中药组合物 | |
| CN112494606A (zh) | 治疗筋骨、风湿类疼痛的中药组合物及其制备方法和应用 | |
| CN102247519A (zh) | 治疗类风湿性关节炎的中药配方 | |
| CN102552705A (zh) | 一种用于治疗腰椎间盘突出、股骨头坏死的中药胶囊 | |
| CN102579672A (zh) | 一种治疗骨质增生和腰椎间盘突出的药物 | |
| CN103127458A (zh) | 一种治疗骨关节肌肉疼痛的药物 | |
| CN102512560A (zh) | 一种治疗痹症的中药组合物 | |
| CN106139015A (zh) | 一种治疗颈肩腰腿痛的中药组合物 | |
| CN102600251B (zh) | 一种治疗类风湿关节炎的中药制剂 | |
| CN102091169A (zh) | 一种具有补益肝肾、活血化瘀、祛风寒湿的中药胶囊 | |
| CN106362066A (zh) | 一种治疗风湿类风湿性疾病的药酒及其制备方法 | |
| CN101530522B (zh) | 治疗风寒湿痛的中药制剂 | |
| CN103083489B (zh) | 治腰椎病、颈椎病、骨质增生早期、陈年旧伤的中药酒剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080917 Termination date: 20120421 |
